The present invention relates to the detection of impaired microvascular capillary blood flow in muscle and in particular provides methods of diagnosis and treatment of diabetes and related pathological states where insulin resistance of muscle occurs.
A number of laboratories have now reported an effect of insulin to increase total blood flow to muscle and that this effect is impaired in states of insulin resistance (1-3). However, the role of the increase in total blood flow mediated by insulin is controversial. Several research groups claim that insulin-mediated changes in total blood flow relate poorly to muscle glucose uptake under a number of circumstances, including insulin dose and time course (4-6). In addition there have been studies where total flow changes persist when glucose uptake is inhibited (7,8). Also, most vasodilators that augment total blood flow to the limbs do not enhance insulin action nor do they overcome insulin resistance (9, 10).
The applicants have shown that hormone and nutrient access by regulating flow between nutritive and non-nutritive flow routes in muscle is a central process in controlling both muscle metabolism and function. It has also been shown that restriction of insulin and glucose access by pharmacologically manipulating flow to be predominantly non-nutritive, creating a state of insulin resistance. The applicants then searched for a method that could detect changes in the proportion of nutritive (capillary) to non-nutritive blood flow in this tissue that might have application in vivo and ultimately to humans. Marker enzymes located in one or other of the two vascular networks (nutritive or non-nutritive) were to provide the key. Thus a first method was developed which involved 1-methylxanthine (1-MX) (20), as an exogenous substrate for xanthine oxidase, an enzyme shown by others to reside predominantly in capillary (nutritive) endothelial cells (21). 1-MX was infused intra-arterially and its metabolite 1-methyl urate measured in venous blood by HPLC; the extent of conversion a reflection of capillary exposure. Characterization under a number of conditions revealed that 1-MX metabolism was indeed directly proportional to nutritive, or capillary flow, which in the constant-flow perfused hindlimb system could be altered by applying various vasoconstrictors or by simulating exercise. The 1-MX method was tested in vivo using the hyperinsulinaemic euglycaemic clamp in rats and it was shown for the first time that insulin acted directly to recruit capillary flow in muscle. Further work showed that pharmacological manipulation to decrease the proportion of nutritive blood flow by an infused vasoconstrictor, created a state of insulin resistance. These latter findings directly linked blood pressure through blood redistribution to insulin resistance in vivo—a situation that is evident from a number of epidemiological studies of human populations. In addition, a close link between capillary recruitment and muscle glucose uptake began to emerge from these and previous 1-MX studies.
A second method was devised using the latest technologies in ultrasound.
The ultrasound method relies on the increased echogenicity of microbubbles which are continuously infused intravenously during data acquisition. The acoustic signal that is generated from the microbubbles when exposed to ultrasound produces tissue opacification which is proportional to the number of microbubbles within the ultrasound beam. Using harmonic pulsing methods essentially all microbubbles within the ultrasound beam are destroyed in response to a single pulse of high-energy ultrasound and an image is obtained. In the time interval between subsequent pulsing episodes, microbubbles flowing into the tissue are replenished within the beam and affect the intensity of the signal from the next high energy pulse. Repeating this process with pulse delays between 50 msec and 20 sec, the beam will be fully replenished and further increases in the time between each pulsing interval will not produce a change to tissue opacification. The rate of microbubble reappearance within the ultrasound beam provides an indication of capillary velocity and the degree of tissue opacification provides a measurement of capillary blood volume (CBV). Images are background-subtracted from images from a pulsing interval of 1000 ms which represents the replenishment of arteries and arterioles thus providing a measurement of capillary flow.
The plateau tissue opacification (measured as videointensity) is the determination of capillary blood volume. Using this approach, changes in capillary blood volume in response to insulin and exercise were assessed in the skeletal muscle of the rat hindlimb in vivo and compared to data obtained using 1-MX metabolism. Compared to baseline values, saline-infusion resulted in little change in capillary blood volume whereas marked increases in capillary blood volume occurred during euglycemic insulin clamp (3 mU/min/kg). Preliminary studies demonstrated that Contrast Enhanced Ultrasound (CEU) data correlates well with 1-MX metabolism data, and that capillary blood volume increases 2-3 fold during these physiologic doses of insulin. A particular advantage of the ultrasound method is that it is relatively non-invasive and is suitable for human use thereby opening up possibilities for its use in diagnosis and the monitoring of outcomes from therapeutic interventions.
Therefore, from these studies a routine diagnostic test emerges where impaired response to a signal, for example insulin, in terms of capillary recruitment can be made. This would take the form of measuring the response to a number of possible stimuli that would be expected to lead to an increased signal reflecting capillary recruitment. For insulin the stimuli may include: the response to a standard meal; insulin infusion; insulin injection; insulin inhalation; oral insulin releasing drugs; oral insulin enhancing drugs; or a combination of the aforementioned; or exercise.
Patients where the techniques and methods of the invention outlined above would be applicable include those with type 2 diabetes, type 1 diabetes, hypertension, obesity, a combination of the aforementioned and critical care patients.
In one aspect the invention provides a method of measuring changes in microvascular capillary flow in a predetermined region in a subject comprising:
The ultrasound contrast medium may be microbubbles and is most preferably albumin microbubbles, although other contrast media may be used including microbubbles of similar size (3-4 micrometres diameter) and echo characteristics. e.g. phospholipid microbubbles.
The ultrasound image may be obtained by using contrast enhanced ultrasound.
The defined signal can be any thing potentially or actually affecting microvascular capillary flow; including insulin applied to said capillaries, a drug intended to increase or decrease microvascular capillary flow or a defined level of exercise applied to a muscle area associated with said capillaries.
In another aspect the invention provides a diagnostic method to differentiate normal from abnormal responses in microvascular capillaries to the application of a defined signal comprising the use of the above method to measure microvascular capillary flow in a predetermined region in a subject in response to said defined signal when compared to the flow in a control microvascular capillary region.
In another aspect the invention provides a diagnostic method incorporating the direct measurement of change in microvascular capillary flow at the source using the measurement methods as previously set out.
In another aspect the invention provides a method for determining changes in nutritive capillary recruitment using the measurement methods as previously set out.
In another aspect the invention provides a method of diagnosis of any one or a combination of conditions including Type 1 &2 diabetes, hypertension, obesity and critical care patients comprising:
The defined signal may be insulin.
In order that the nature of the present invention may be more clearly understood details are given in the following particularly preferred embodiments relating to the equipment, materials and how the techniques of the invention are administered and data analyzed. The embodiments are not to be taken as limiting the scope of the invention.
Equipment
Ultrasound equipment can be Sonos 5500, Hewlett-Packard (Andover, Mass.) or equivalent. For example an HDI-5000 by ATL Ultrasound was also found to be suitable.
Microbubbles
Albumin microbubbles containing a mixture of air and perfluorocarbon gas (Optison®, Mallinckrodt Medical, Inc. St Louis, Mo.).
Procedure
This is as applied to the human forearm. Details on the forearm procedure can be found in published work which is herein incorporated by reference (27-29) and details for the use of contrast enhanced ultrasound/microbubbles in skeletal muscle are based on its use to study myocardial blood flow (30,31).
a) In response to a defined dose of insulin infused intra-arterially.
Typically, in response to low doses of insulin 0.01 to 0.05 mU/min/kg infused locally into the brachial artery, plasma insulin rises by 70-350 pM in blood perfusing forearm muscle with little or no effect on the systemic insulin, glucose, FFA, catecholamines or amino acid concentrations (29). As a result, the isolated effect of local insulin on total blood flow into the arm and glucose balance across the arm can be measured. In addition, capillary recruitment in the forearm flexor muscle can be measured using CEU. Total forearm blood flow is measured on each subject by two techniques: capacitance plethysmography and brachial artery ultrasound. For the Doppler flow measurements, an ultrasound system (Sonos 5500, Hewlett-Packard, Andover, Mass.) with a linear-array transducer is used with a transmit frequency of 7.5 MHz to allow 2-D imaging of the brachial artery in the long axis. Brachial artery diameter is measured 2 cm proximal to the tip of the arterial catheter at peak systole using on-line video calipers. A pulsed-wave Doppler sample blood volume is placed at the same location in the center of the vessel and the mean brachial artery blood velocity measured using on-line angle correction and analysis software. Brachial artery blood flow is calculated from 2-D Doppler ultrasound data using the equation: Q=vπ·(d/2)2
To measure capillary recruitment with CEU, a suspension of albumin microbubbles is infused intravenously in the contra-lateral arm while 2D imaging of the deep flexor muscles of the test forearm is performed (
Typical data for normal healthy subjects are shown in
Typical data for lean normal and obese subjects are compared in
Methods: Subjects:—11 Lean Healthy adults (23.8±0.8 kg/m2 BMI, 29±2 years old) and 6 Obese healthy adults (34.6±1.8 kg/m2 BMI, 39±3 years old). CEU estimation of microvascular blood volume (MBV) and flow velocity (MBV) in forearm skeletal muscle measured by video intensity. Catheter placement in brachial artery in one forearm for insulin infusion and deep retrograde antecubital vein for blood sampling. Net glucose metabolism is measured over time by arterio-venous concentration difference multiplied by total blood flow. Protocol: Insulin was infused intra-arterially at a rate of 0.05 mU/min/kg for 4 hours. Brachial artery and bilateral deep venous blood samples were obtained at baseline and post-insulin infusion for measurements of glucose, lactate, oxygen saturation and insulin levels. Doppler U/S measured total blood flow. MBV and MBF were assessed using CEU.
In lean individuals, physiologic hyperinsulinemia increases microvascular blood volume suggesting evidence of capillary recruitment in forearm skeletal muscle. This action of insulin can occur without significant changes in total blood flow. In insulin-resistant obese individuals, this action of insulin is absent.
b) In response to a standard meal which in healthy individuals raises the insulin levels 34 fold above the pre-meal level. Leg glucose uptake increases at least four fold by 30 minutes after the meal (34), which consists of pizza (8.5 kcal/kg body weight, containing 75 g as carbohydrate, protein 37 g and fat 17 g). Other details are as above in a).
c) In response to a defined amount of exercise. The forearm is exercised by contracting to 75% maximum using a digital grip strength dynamometer (Takei Scientific Co) 12 times each minute for 2 minutes, then 3 times each minute for the next 20 min. During the last 10 min, quadruplicate blood samples, total blood flow and CEU measurements are repeated as at basal in both forearms. This leads to a 3-fold increase in forearm total blood flow. Other details are as above in a). Typical data for a lean normal subject engaged in exercising the forearm are shown in
Comparing
d) In response to a drug intended and designed to act specifically by increasing skeletal muscle capillary blood flow. These will be taken by the normal oral route and intended to achieve the afore-mentioned effect on muscle capillary blood flow acutely (within 20-60 minutes).
A number of responses were recorded on normal healthy male and female individuals at various ages. This provided a reference set of data which reflects a normal response to the defined dose of insulin and the defined exercise routine for each sex at each age. The male response could reasonably be expected to be larger than that of females at each age. However, the response would be expected to decline with age after about forty. Individuals considered to have muscle insulin resistance showed reduced responses to the defined dose of insulin and the standard meal without change to the response to exercise. This group would include type 1 and 2 diabetics, hypertensives, and the obese (>30 Body Mass Index). Critical care patients would show markedly decreased responses to all three, defined insulin dose, standard meal, and defined exercise regimen.
The efficacy of drugs intended to ameliorate skeletal muscle insulin resistance by specifically acting to increase capillary recruitment or by enhancing insulin's action to do this, will increase the response determined by CEU to the defined insulin dose, the standard meal, but not to the exercise regimen. Little or no effect is expected by these drugs in normal healthy individuals.
Any discussion of references, documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application. Any such references are herein incorporated in the application.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Number | Date | Country | Kind |
---|---|---|---|
PR 5769 | Jun 2001 | AU | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/AU02/00753 | 6/11/2002 | WO |